Drug Information Association's 44th Annual Meeting June 22-26, 2008, Boston, MA

February 11, 2008 - Today, Brett Mensh, M.D., PhD. joins Accélère as Medical Director to lead investigator relations at site-based research centers and to build awareness of Accelere's capabilities within the medical staff of research sponsors. Recently at Pipeline Strategy Group as Vice President of Clinical Development, Brett has focused on the quality and efficiency of clinical trial design and execution. Prior to Pipeline, Brett served as Medical Director of Omneuron where he designed multicenter clinical trials for their novel device to treat chronic pain. Brett spent 8 years on the research faculty at Columbia working on pharmaceutical sponsored trials for Alzheimer's and Major Depressive Disorder before Omneuron and on the research faculty at Harvard/M.I.T prior to Columbia. Brett received his BSE in Biomedical Engineering from Duke University and his M.D. and PhD from Baylor College of Medicine.

January 28, 2008 - Accélère announced today that it will appoint John Kish as Chairman of the Board of Directors. John recently served as President and CEO of Wyse Technologies, a $200M market leader in the thin client market place. Previously he served as President & CEO of Cacheon, an on-demand application migration software located in San Francisco and of Boston-based Verbind, a real-time e-marketing solutions company. Verbind pioneered the use of functional state technology into a behavioral targeting engine. Kish also served as President and CEO of Boston-based Domain Solutions Corporation, a privately held $50M software company that delivered clinical trials management and adverse events reporting software to the pharmaceutical industry as well as real-time process optimization technologies to the manufacturing industry.

John will drive the company's strategy and execution of the company's first round of institutional financing. John will also provide additional support for developing key strategic relationships with healthcare institutions, pharmaceutical companies and technology suppliers.

January 25, 2008 - Today, Accélère completed the conversion of its 3 earlier offerings of convertible debt into Series A1 preferred shares. In addition, the company secured additional financing with a new 2-year convertible note that can convert to its Series A2 offering, designed for institutional investors later this year. To date, the company has raised $2M from a team of private investors and proceeds have funded technology development, clinical site deployment, sales and related company operations since March 2005. "With our accelerating growth in commercial activity, it's vital that we clean up our balance sheet and prepare the company for institutional investors", stated Accelere's CEO, David Chen. "With the close of 2007, we end the "test" phase of our business, in terms of technology, user adoption, partnership alignment and deal structure. We know our top customers and partners want scale that brings a material difference to their clinical trials. As a company we need to get our network to critical mass as quickly as possible. There is nothing like money to help solve this problem and we are in prime position to invest our network growth around our existing customers and partners."